SciBase Secures $0.6M Order from Castle Biosciences to Accelerate Dermatology Studies
Event summary
- SciBase received a $0.6M order from Castle Biosciences for Nevisense Go devices and electrodes to accelerate an ongoing clinical study and prepare for a second study.
- The collaboration, initiated in 2025, focuses on predicting relapses in atopic dermatitis (AD).
- Deliveries are expected to begin in Q4 2026.
- SciBase's Nevisense Go combines AI and EIS technology for dermatological diagnostics.
The big picture
SciBase's collaboration with Castle Biosciences underscores the growing intersection of AI and dermatology, particularly in predictive diagnostics for chronic skin conditions like atopic dermatitis. The $0.6M order highlights the scalability of SciBase's Nevisense Go technology and its potential to become a standard tool in dermatological research. The partnership also reflects a broader industry trend toward leveraging advanced diagnostics to improve patient outcomes and reduce healthcare costs.
What we're watching
- Collaboration Expansion
- Whether the acceleration of the initial study and preparation for a second study signal a deeper, long-term partnership between SciBase and Castle Biosciences.
- Market Validation
- How the success of these studies could validate SciBase's AI-based diagnostic technology in the broader dermatology market.
- Revenue Growth
- The pace at which additional orders from Castle Biosciences or other partners could contribute to SciBase's revenue growth.
Related topics